Financial - Capital Markets
Build Your Comparison
Side-by-side financial analysisStock Comparison
NAKA vs OPRX vs TALK vs KO vs DOCS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Care Facilities
Beverages - Non-Alcoholic
Medical - Healthcare Information Services
NAKA vs OPRX vs TALK vs KO vs DOCS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Financial - Capital Markets | Medical - Healthcare Information Services | Medical - Care Facilities | Beverages - Non-Alcoholic | Medical - Healthcare Information Services |
| Market Cap | $79M | $100M | $871M | $348.25B | $3.87B |
| Revenue (TTM) | $4M | $107M | $238M | $49.28B | $645M |
| Net Income (TTM) | $-290M | $7M | $1M | $13.70B | $196M |
| Gross Margin | -376.0% | 69.0% | 42.2% | 61.7% | 89.1% |
| Operating Margin | -82.2% | 13.6% | -1.2% | 29.3% | 33.3% |
| Forward P/E | — | 5.6x | 37.0x | 24.7x | 14.4x |
| Total Debt | $210M | $26M | $0.00 | $45.49B | $10M |
| Cash & Equiv. | $23M | $23M | $37M | $10.27B | $219M |
NAKA vs OPRX vs TALK vs KO vs DOCS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 24 | Jun 26 | Return |
|---|---|---|---|
| Nakamoto Inc. (NAKA) | 100 | 3.7 | -96.3% |
| OptimizeRx Corporat… (OPRX) | 100 | 44.1 | -55.9% |
| Talkspace, Inc. (TALK) | 100 | 198.5 | +98.5% |
| The Coca-Cola Compa… (KO) | 100 | 128.6 | +28.6% |
| Doximity, Inc. (DOCS) | 100 | 74.6 | -25.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NAKA vs OPRX vs TALK vs KO vs DOCS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, NAKA doesn't own a clear edge in any measured category.
OPRX ranks third and is worth considering specifically for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 2.18
- Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
- Lower P/E (5.6x vs 24.7x)
TALK carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 0.73, current ratio 6.38x
- 22.0% revenue growth vs NAKA's -33.0%
- Beta 0.73 vs NAKA's 2.88
- +85.1% vs NAKA's -99.3%
KO is the clearest fit if your priority is long-term compounding.
- 118.2% 10Y total return vs TALK's -48.5%
- 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
DOCS is the #2 pick in this set and the best alternative if sleep-well-at-night and valuation efficiency is your priority.
- Lower volatility, beta 0.75, Low D/E 1.1%, current ratio 6.09x
- PEG 0.28 vs KO's 2.21
- 30.4% margin vs NAKA's -74.0%
- 16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 22.0% revenue growth vs NAKA's -33.0% | |
| Value | Lower P/E (5.6x vs 24.7x) | |
| Quality / Margins | 30.4% margin vs NAKA's -74.0% | |
| Stability / Safety | Beta 0.73 vs NAKA's 2.88 | |
| Dividends | 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +85.1% vs NAKA's -99.3% | |
| Efficiency (ROA) | 16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1% |
NAKA vs OPRX vs TALK vs KO vs DOCS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NAKA vs OPRX vs TALK vs KO vs DOCS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 2 of 6 categories
OPRX leads 1 • TALK leads 1 • KO leads 1 • NAKA leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 12573.5x NAKA's $4M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to NAKA's -74.0%. On growth, NAKA holds the edge at +3.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4M | $107M | $238M | $49.3B | $645M |
| EBITDAEarnings before interest/tax | -$320M | $19M | $2M | $15.5B | $227M |
| Net IncomeAfter-tax profit | -$290M | $7M | $1M | $13.7B | $196M |
| Free Cash FlowCash after capex | -$46M | $14M | -$6M | $12.6B | $215M |
| Gross MarginGross profit ÷ Revenue | -3.8% | +69.0% | +42.2% | +61.7% | +89.1% |
| Operating MarginEBIT ÷ Revenue | -82.2% | +13.6% | -1.2% | +29.3% | +33.3% |
| Net MarginNet income ÷ Revenue | -74.0% | +6.4% | +0.5% | +27.8% | +30.4% |
| FCF MarginFCF ÷ Revenue | -11.7% | +13.4% | -2.7% | +25.5% | +33.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.6% | -9.5% | +18.2% | +12.1% | +5.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -88.4% | +78.0% | — | +18.2% | -67.7% |
Valuation Metrics
OPRX leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 19.7x trailing earnings, OPRX trades at a 85% valuation discount to TALK's 130.0x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.40x vs KO's 2.38x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $79M | $100M | $871M | $348.2B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $266M | $103M | $834M | $383.5B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -0.43x | 19.70x | 130.00x | 26.62x | 21.10x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.65x | 36.96x | 24.75x | 14.43x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.38x | 0.40x |
| EV / EBITDAEnterprise value multiple | — | 6.26x | 138.33x | 25.89x | 17.02x |
| Price / SalesMarket cap ÷ Revenue | 43.19x | 0.91x | 3.81x | 7.26x | 6.00x |
| Price / BookPrice ÷ Book value/share | 0.10x | 0.79x | 7.72x | 10.18x | 4.33x |
| Price / FCFMarket cap ÷ FCF | — | 5.35x | — | 65.76x | — |
Profitability & Efficiency
DOCS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-85 for NAKA. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), OPRX scores 7/9 vs NAKA's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -84.8% | +5.5% | +1.0% | +41.1% | +19.4% |
| ROA (TTM)Return on assets | -56.5% | +4.0% | +0.9% | +13.1% | +16.5% |
| ROICReturn on invested capital | -42.1% | +6.8% | +3.9% | +15.8% | +19.8% |
| ROCEReturn on capital employed | -76.2% | +7.8% | +2.7% | +17.3% | +20.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 6 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.41x | 0.20x | — | 1.33x | 0.01x |
| Net DebtTotal debt minus cash | $187M | $3M | -$37M | $35.2B | -$209M |
| Cash & Equiv.Liquid assets | $23M | $23M | $37M | $10.3B | $219M |
| Total DebtShort + long-term debt | $210M | $26M | $0 | $45.5B | $10M |
| Interest CoverageEBIT ÷ Interest expense | -24.72x | 2.84x | 1.89x | 10.70x | — |
Total Returns (Dividends Reinvested)
TALK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,313 today (with dividends reinvested), compared to $374 for NAKA. Over the past 12 months, TALK leads with a +85.1% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors TALK at 62.1% vs NAKA's -66.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -72.3% | -57.2% | +48.1% | +18.6% | -52.2% |
| 1-Year ReturnPast 12 months | -99.3% | -61.4% | +85.1% | +17.7% | -63.0% |
| 3-Year ReturnCumulative with dividends | -96.3% | -64.6% | +326.2% | +42.6% | -36.1% |
| 5-Year ReturnCumulative with dividends | -96.3% | -89.8% | -47.3% | +63.1% | -61.0% |
| 10-Year ReturnCumulative with dividends | -96.3% | +56.9% | -48.5% | +118.2% | -61.0% |
| CAGR (3Y)Annualised 3-year return | -66.6% | -29.2% | +62.1% | +12.6% | -13.9% |
Risk & Volatility
Evenly matched — TALK and KO each lead in 1 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.4% from its 52-week high vs NAKA's 0.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.88x | 2.18x | 0.73x | -0.20x | 0.75x |
| 52-Week HighHighest price in past year | $679.20 | $22.25 | $5.23 | $84.04 | $76.51 |
| 52-Week LowLowest price in past year | $0.38 | $4.57 | $2.22 | $65.35 | $17.16 |
| % of 52W HighCurrent price vs 52-week peak | +0.7% | +23.9% | +99.4% | +96.3% | +27.0% |
| RSI (14)Momentum oscillator 0–100 | 35.4 | 46.1 | 56.8 | 60.8 | 40.8 |
| Avg Volume (50D)Average daily shares traded | 274K | 442K | 1.5M | 12.7M | 3.9M |
Analyst Outlook
KO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: NAKA as "Buy", OPRX as "Buy", TALK as "Hold", KO as "Buy", DOCS as "Hold". Consensus price targets imply 219.5% upside for OPRX (target: $17) vs 1.0% for TALK (target: $5). KO is the only dividend payer here at 2.52% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $8.00 | $17.00 | $5.25 | $86.13 | $29.47 |
| # AnalystsCovering analysts | 2 | 15 | 10 | 48 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +2.5% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | — | 56 | — |
| Dividend / ShareAnnual DPS | — | — | — | $2.04 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | 0.0% | +2.0% | +0.2% | +11.2% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OPRX leads in 1 (Valuation Metrics). 1 tied.
NAKA vs OPRX vs TALK vs KO vs DOCS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NAKA or OPRX or TALK or KO or DOCS a better buy right now?
For growth investors, Talkspace, Inc.
(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). OptimizeRx Corporation (OPRX) offers the better valuation at 19. 7x trailing P/E (5. 6x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NAKA or OPRX or TALK or KO or DOCS?
On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 19.
7x versus Talkspace, Inc. at 130. 0x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 28x versus The Coca-Cola Company's 2. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NAKA or OPRX or TALK or KO or DOCS?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +63.
1%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: KO returned +118. 2% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NAKA or OPRX or TALK or KO or DOCS?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately -1540% more volatile than KO relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — NAKA or OPRX or TALK or KO or DOCS?
By revenue growth (latest reported year), Talkspace, Inc.
(TALK) is pulling ahead at 22. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NAKA or OPRX or TALK or KO or DOCS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 30. 4% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NAKA or OPRX or TALK or KO or DOCS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 28x versus The Coca-Cola Company's 2. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5. 6x forward P/E versus 37. 0x for Talkspace, Inc. — 31. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 219. 5% to $17. 00.
08Which pays a better dividend — NAKA or OPRX or TALK or KO or DOCS?
In this comparison, KO (2.
5% yield) pays a dividend. NAKA, OPRX, TALK, DOCS do not pay a meaningful dividend and should not be held primarily for income.
09Is NAKA or OPRX or TALK or KO or DOCS better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +118. 2% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +118. 2%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NAKA and OPRX and TALK and KO and DOCS?
These companies operate in different sectors (NAKA (Financial Services) and OPRX (Healthcare) and TALK (Healthcare) and KO (Consumer Defensive) and DOCS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NAKA is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; TALK is a small-cap high-growth stock; KO is a large-cap quality compounder stock; DOCS is a small-cap quality compounder stock. KO pays a dividend while NAKA, OPRX, TALK, DOCS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.